Display options
Cite
Kedia S, Bhatia V, Thareja S, et al. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial. World J Gastrointest Pharmacol Ther. 2017;8(2):147-154doi: 10.4292/wjgpt.v8.i2.147.
Kedia, S., Bhatia, V., Thareja, S., Garg, S., Mouli, V. P., Bopanna, S., Tiwari, V., Makharia, G., & Ahuja, V. (2017). Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial. World journal of gastrointestinal pharmacology and therapeutics, 8(2), 147-154. https://doi.org/10.4292/wjgpt.v8.i2.147
Kedia, Saurabh, et al. "Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial." World journal of gastrointestinal pharmacology and therapeutics vol. 8,2 (2017): 147-154. doi: https://doi.org/10.4292/wjgpt.v8.i2.147
Kedia S, Bhatia V, Thareja S, Garg S, Mouli VP, Bopanna S, Tiwari V, Makharia G, Ahuja V. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial. World J Gastrointest Pharmacol Ther. 2017 May 06;8(2):147-154. doi: 10.4292/wjgpt.v8.i2.147. PMID: 28533925; PMCID: PMC5421114.
Copy Download .nbib Format: NLM
Share it on

World J Gastrointest Pharmacol Ther. 2017 May 06;8(2):147-154. doi: 10.4292/wjgpt.v8.i2.147.

Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial.

World journal of gastrointestinal pharmacology and therapeutics

Saurabh Kedia, Vikram Bhatia, Sandeep Thareja, Sushil Garg, Venigalla Pratap Mouli, Sawan Bopanna, Veena Tiwari, Govind Makharia, Vineet Ahuja

Affiliations

  1. Saurabh Kedia, Sushil Garg, Venigalla Pratap Mouli, Sawan Bopanna, Veena Tiwari, Govind Makharia, Vineet Ahuja, Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi 110029, India.

PMID: 28533925 PMCID: PMC5421114 DOI: 10.4292/wjgpt.v8.i2.147

Abstract

AIM: To evaluate the role of oral curcumin in inducing clinical remission in patients with mild to moderate ulcerative colitis (UC).

METHODS: A prospective randomized double-blind placebo-controlled trial comparing the remission inducing effect of oral curcumin and mesalamine 2.4 g with placebo and mesalamine 2.4 g in patients of ulcerative colitis with mild to moderate severity was conducted from January 2003 to March 2005. The included patients received 1 capsule thrice a day of placebo or curcumin (150 mg) for 8 wk. Patients were evaluated clinically and endoscopically at 0, 4 and 8 wk. The primary outcome was clinical remission at 8 wk and secondary outcomes were clinical response, mucosal healing and treatment failure at 8 wk. The primary analysis was intention to treat worst case scenario (ITT-WCS).

RESULTS: Of 300 patients with UC, 62 patients (curcumin: 29, placebo: 33) fulfilled the inclusion criteria and were randomized at baseline. Of these, 21 patients did not complete the trial, 41 patients (curcumin: 16, placebo: 25) finally completed 8 wk. There was no significant difference in rates of clinical remission (31.3%

CONCLUSION: Low dose oral curcumin at a dose of 450 mg/d was ineffective in inducing remission in mild to moderate cases of UC.

Keywords: Curcumin; Mesalamine; Mucosal healing; Ulcerative colitis; Ulcerative colitis disease activity index

Conflict of interest statement

Conflict-of-interest statement: No conflict of interest for all authors.

References

  1. J Crohns Colitis. 2014 Mar;8(3):208-14 - PubMed
  2. N Engl J Med. 2002 Aug 8;347(6):417-29 - PubMed
  3. Biochem Pharmacol. 2000 Jun 1;59(11):1445-57 - PubMed
  4. Cochrane Database Syst Rev. 2012 Oct 17;10:CD008424 - PubMed
  5. J Immunol. 2005 Jun 15;174(12):8116-24 - PubMed
  6. Gastroenterology. 2002 Dec;123(6):1912-22 - PubMed
  7. Autoimmun Rev. 2004 Jul;3(5):394-400 - PubMed
  8. Br J Pharmacol. 2003 May;139(2):209-18 - PubMed
  9. J Clin Immunol. 2007 Jan;27(1):19-35 - PubMed
  10. Ciba Found Symp. 1994;185:153-64; discussion 164-8 - PubMed
  11. Anticancer Res. 2001 Jul-Aug;21(4B):2895-900 - PubMed
  12. J Dig Dis. 2010 Jun;11(3):134-47 - PubMed
  13. Mol Aspects Med. 1993;14(3):171-90 - PubMed
  14. FEBS Lett. 2000 Oct 13;483(1):78-82 - PubMed
  15. Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):390-407 - PubMed
  16. Gut. 1998 Apr;42(4):477-84 - PubMed
  17. N Engl J Med. 1987 Dec 24;317(26):1625-9 - PubMed
  18. Pharm Dev Technol. 2016 Aug;21(5):630-5 - PubMed
  19. Crit Rev Food Sci Nutr. 2004;44(2):97-111 - PubMed
  20. Gastroenterology. 1987 Jun;92(6):1894-8 - PubMed
  21. Drug Deliv. 2016;23 (1):55-62 - PubMed
  22. Clin Gastroenterol Hepatol. 2006 Dec;4(12):1502-6 - PubMed
  23. Br Med J. 1964 Jan 11;1(5375):89-92 - PubMed
  24. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1444-9.e1 - PubMed
  25. World J Gastroenterol. 2005 Mar 28;11(12):1747-52 - PubMed
  26. Gastroenterology. 1998 Jul;115(1):182-205 - PubMed
  27. Immunopharmacol Immunotoxicol. 2005;27(3):485-97 - PubMed
  28. J Clin Invest. 1997 Dec 1;100(11):2671-9 - PubMed
  29. Planta Med. 1991 Feb;57(1):1-7 - PubMed
  30. Curr Pharm Des. 2009;15(18):2087-94 - PubMed
  31. Hum Mol Genet. 2001 Mar 1;10(5):445-56 - PubMed
  32. J Immunol. 1999 Sep 15;163(6):3474-83 - PubMed
  33. Am J Physiol Gastrointest Liver Physiol. 2003 Jul;285(1):G235-43 - PubMed

Publication Types